Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

H. Butzkueven, T. Kalincik, F. Patti, M. Slee, B. Weinstock-Guttman, K. Buzzard, O. Skibina, R. Alroughani, A. Prat, M. Girard, D. Horakova, EK. Havrdova, A. Van der Walt, S. Eichau, R. Hyde, N. Campbell, K. Bodhinathan, T. Spelman, MSBase Investigators

. 2024 ; 17 (-) : 17562864231221331. [pub] 20240226

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24005723

BACKGROUND: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance. OBJECTIVES: Evaluate long-term clinical outcomes in patients with MS who initiated treatment with either natalizumab or a BRACETD therapy (interferon beta, glatiramer acetate, teriflunomide, or dimethyl fumarate). DESIGN: This retrospective analysis utilized data from MSBase to create a matched population allowing comparison of first-line natalizumab to first-line BRACETD. METHODS: This study included patients who initiated treatment either with natalizumab or a BRACETD DMT within 1 year of MS diagnosis and continued treatment for ⩾6 months, after which patients could switch DMTs or discontinue treatment. Patients had a minimum follow-up time of ⩾60 months from initiation. A subgroup analysis compared the natalizumab group to patients in the BRACETD group who escalated therapy after 6 months. Outcomes included unadjusted annualized relapse rates (ARRs), time-to-first relapse, time-to-first confirmed disability improvement (CDI), and time-to-first confirmed disability worsening (CDW). RESULTS: After 1:1 propensity score matching, 355 BRACETD patients were matched to 355 natalizumab patients. Patients initiating natalizumab were less likely to experience a relapse over the duration of follow-up, with ARRs [95% confidence interval (CI)] of 0.080 (0.070-0.092) for natalizumab patients and 0.191 (0.178-0.205) for BRACETD patients (p < 0.0001). A Cox regression model of time-to-first relapse showed a reduced risk of relapse for natalizumab patients [hazard ratio (95% CI) of 0.52 (0.42-0.65); p < 0.001] and a more favorable time-to-first CDI. The risk of CDW was similar between groups. The subgroup analysis showed an increased relapse risk as well as a significantly higher risk of CDW for BRACETD patients. CONCLUSION: Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005723
003      
CZ-PrNML
005      
20240412131019.0
007      
ta
008      
240405e20240226enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/17562864231221331 $2 doi
035    __
$a (PubMed)38414723
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Butzkueven, Helmut $u Department of Neuroscience, Central Clinical School, Alfred Campus, Monash University, 6/99 Commercial Road, Melbourne, VIC 3004, Australia $u Department of Neurology, Box Hill Hospital, Monash University, Box Hill, VIC, Australia $1 https://orcid.org/0000000339408727
245    10
$a Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies / $c H. Butzkueven, T. Kalincik, F. Patti, M. Slee, B. Weinstock-Guttman, K. Buzzard, O. Skibina, R. Alroughani, A. Prat, M. Girard, D. Horakova, EK. Havrdova, A. Van der Walt, S. Eichau, R. Hyde, N. Campbell, K. Bodhinathan, T. Spelman, MSBase Investigators
520    9_
$a BACKGROUND: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance. OBJECTIVES: Evaluate long-term clinical outcomes in patients with MS who initiated treatment with either natalizumab or a BRACETD therapy (interferon beta, glatiramer acetate, teriflunomide, or dimethyl fumarate). DESIGN: This retrospective analysis utilized data from MSBase to create a matched population allowing comparison of first-line natalizumab to first-line BRACETD. METHODS: This study included patients who initiated treatment either with natalizumab or a BRACETD DMT within 1 year of MS diagnosis and continued treatment for ⩾6 months, after which patients could switch DMTs or discontinue treatment. Patients had a minimum follow-up time of ⩾60 months from initiation. A subgroup analysis compared the natalizumab group to patients in the BRACETD group who escalated therapy after 6 months. Outcomes included unadjusted annualized relapse rates (ARRs), time-to-first relapse, time-to-first confirmed disability improvement (CDI), and time-to-first confirmed disability worsening (CDW). RESULTS: After 1:1 propensity score matching, 355 BRACETD patients were matched to 355 natalizumab patients. Patients initiating natalizumab were less likely to experience a relapse over the duration of follow-up, with ARRs [95% confidence interval (CI)] of 0.080 (0.070-0.092) for natalizumab patients and 0.191 (0.178-0.205) for BRACETD patients (p < 0.0001). A Cox regression model of time-to-first relapse showed a reduced risk of relapse for natalizumab patients [hazard ratio (95% CI) of 0.52 (0.42-0.65); p < 0.001] and a more favorable time-to-first CDI. The risk of CDW was similar between groups. The subgroup analysis showed an increased relapse risk as well as a significantly higher risk of CDW for BRACETD patients. CONCLUSION: Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kalincik, Tomas $u Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia
700    1_
$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia', University of Catania, Catania, Italy $1 https://orcid.org/0000000269230846
700    1_
$a Slee, Mark $u Flinders University, Adelaide, SA, Australia
700    1_
$a Weinstock-Guttman, Bianca $u Department of Neurology, Jacobs MS Center for Treatment and Research, Buffalo, NY, USA $1 https://orcid.org/000000016732151X
700    1_
$a Buzzard, Katherine $u Department of Neurology, Box Hill Hospital, Melbourne, VIC, Australia
700    1_
$a Skibina, Olga $u Department of Neurology, Box Hill Hospital, Melbourne, VIC, Australia
700    1_
$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait $1 https://orcid.org/0000000154365804
700    1_
$a Prat, Alexandre $u CHUM and Universite de Montreal, Montreal, QC, Canada
700    1_
$a Girard, Marc $u CHUM and Universite de Montreal, Montreal, QC, Canada
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Van der Walt, Anneke $u Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia $1 https://orcid.org/0000000242787003
700    1_
$a Eichau, Sara $u Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Hyde, Robert $u Biogen, Cambridge, MA, USA, at the time of this analysis
700    1_
$a Campbell, Nolan $u Biogen, Cambridge, MA, USA
700    1_
$a Bodhinathan, Karthik $u Biogen, Cambridge, MA, USA
700    1_
$a Spelman, Tim $u Burnet Institute, Melbourne, VIC, Australia
710    2_
$a MSBase Investigators
773    0_
$w MED00177176 $t Therapeutic advances in neurological disorders $x 1756-2856 $g Roč. 17 (20240226), s. 17562864231221331
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38414723 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412131012 $b ABA008
999    __
$a ok $b bmc $g 2076004 $s 1215485
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 17 $c - $d 17562864231221331 $e 20240226 $i 1756-2856 $m Therapeutic advances in neurological disorders $n Ther Adv Neurol Disord $x MED00177176
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options